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SUMMARY 
The optimization of a new process for the extraction of human coagulation 
factor VIII (FVIII) from plasma with the tailor-made affinity matrix dimethylamino- 
propylcarbamylpentyl-Sepharose CL4B (C3-C5 matrix) is described. First, plasma 
is applied to DEAE-Sephadex A-50 anion exchanger in order to separate a number of 
proteins, including coagulation factors II, IX and X (prothrombin complex), from 
FVIII. Subsequently, the unbound fraction of the ion exchanger, containing FVIII, is 
contacted with the C3-C5 affinity matrix. Optimization of the FVIII affinity chroma- 
tographic procedure is accomplished in terms of the ligand density of the matrix, 
adsorption mode (batch-wise V~YSUS column-wise adsorption and matrix to plasma 
ratio), and conditions of pH and conductivity to be applied on washing and de- 
sorption. In scale-up experiments, by processing 20 1 of plasma, the recovery (340 U 
VIII:C/kg plasma) and the specific activity (s.a.) (1.2 U VIII:C/mg protein) are better 
than those obtained by cryoprecipitation (recovery 300 U VIII:C/kg plasma, s.a. 0.3 
U VIII:C/mg protein). The newly developed process using the specially designed 
C3-C5 affinity matrix has potential application in the process-scale purification of 
FVIII. 
INTRODUCTION 
Preparations of coagulation factor VIII (FVIII) and Von Willebrand factor 
(vWf) are used in the treatment of patients suffering from haemophilia A or Von 
Willebrand’s disease. Cryoprecipitation is the technique most commonly used to re- 
cover these components from human donor plasma’,2. Unfortunately, the FVIII 
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yield and specific activity (s.a.) of cryoprecipitate are usually low: only 40% of FVIII 
in plasma can be recovered with an s.a. of 0.3 U factor VIII activity (VIII:C) per mg 
of protein. As impurities in the cryoprecipitate might cause side effects394, successive 
purification methods have been developed’-” which yield FVIII preparations with 
s.a. varying from 1 to 3000 U VIII:C/mg protein. However, high degrees of puri- 
fication inevitably imply a low recovery; final recoveries of VITI:C of less then 20% 
are common in plasma fractionation on a full process scale. These low recoveries are 
mainly due to the use of cryo.precipitate as the source material for FVIII preparations 
with a higher purity. 
Higher recoveries may be obtained when cryoprecipitation is replaced by a 
more efficient method. Therefore, it was investigated whether direct application of 
(affinity) chromatography to plasma could result in an FVIII preparation which is 
better in terms of recovery and degree of purification. Considering the limited avail- 
ability of human donor plasma, a high recovery was of greater importance in this 
investigation than a high degree of purification. Further, a reproducible and control- 
lable process is necessary to meet the good manufacturing practices (GMP) require- 
ments set for the production of pharmaceuticals (e.g., protein) for use in humans12. 
The synthesis of several affinity matrices, specially developed for isolation of 
FVIII directly from plasma, was reported previously13,‘4. One of these FVIII affinity 
matrices, dimethylaminopropylcarbamylpentyl-Sepharose Cl-4B, proved to be the 
most suitable for the purification of FVIII from plasma14. In this paper, results are 
presented concerning the optimization of a chromatographic FVIII purification pro- 
cedure, with this tailor-made affinity matrix, characterized by a relatively high recov- 
ery and s.a. of FVIII. 
EXPERIMENTAL 
Materials 
Normal plasma pools were prepared from 30-80 donations of citrateephos- 
phatedextrose-adenine (CPDA- 1)-anticoagulated plasma [Central Laboratory of 
the Netherlands Red Cross Blood Transfusion Service (CLB), Amsterdam, The 
TABLE I 
OVERVIEW OF BUFFERS AND THEIR COMPOSITIONS 
Bz@r 
WPe” 
A 
B 
c 
D 
E 
F 
G 
H 
PH 
7.0 
7.0 
7.4 
7.4 
7.4 
Y+ 
1.4 
1.4 
[Sodium chloride] [Sodium metate] [L-Lysine] 
CM) fM) (Ml 
0.18 
2.0 
_ 0.1 0.1 
1.0 0.1 0.1 
xb 
0.17 
Zb 0.1 0.1 
0.04 0.1 
* The buffers contained also 10 mM sodium citrate and 1 mM calcium chloride 
b X = 0.10-0.25 M NaCl; Y = pH 68; Z = 0.25-1.50 M NaCI. 
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Netherlands]. Human serum albumin and specific antisera against human albumin, 
fibronectin, fibrinogen and factor II were from the CLB. DEAE-Sephadex A-50, 
Sepharose CL-4B and chromatographic columns (C10/20, C16/30, C26/30, K50/30 
and BP 113/30) were obtained from Pharmacia (Uppsala, Sweden). Affinity matrices 
with various ligand densities were obtained as described below. All chemicals were 
purchased from Merck (Darmstadt, F.R.G.). In Table I, an overview of the composi- 
tion of the buffers used is presented. 
Synthesis of afJinity matrix 
For synthesis of the affinity matrix, the method described by Riethorst13 was 
used: a known amount (settled gel volume) of Sepharose CL-4B was solvent ex- 
changed from water to dimethylformamide (DMF) by washing the support extensive- 
ly with dry DMF on a sintered-glass filter (G3). Subsequently, the support was activa- 
ted (1.5 h, 20°C) with l,l’-carbonyldiimidazole (CDI). The degree of activation was 
varied by the amount of CDL dissolved in DMF, added to the support (0.10-0.32 
mmol/ml of settled gel in water). The CDI-activated support was washed with DMF 
and, subsequently, 6-aminohexanoic acid was coupled (2O”C, 10 h) by mixing a solu- 
tion of the amino acid in water (pH 12.6) with the gel suspension (0.9 mmol of the 
amino acid per ml of settled gel in water). After coupling, the gel was washed with 
DMF and water, the ligand density of the carboxylic acid end groups on the support 
was determined (see below) and the support was again solvent exchanged to DMF. 
Carboxylic acid end-groups were esterified (20°C 16 h) with N-hydroxysuccinimide 
(4-6 times the amount of carboxylic acid groups) using an equal amount of 1-ethyl-3- 
(3-dimethylaminopropyl)carbodiimide as a coupling agent. After washing with 
DMF, dimethylaminopropylamine (20 times the amount of carboxylic acid groups) 
was coupled onto the matrix (20°C 16 h). After solvent exchange to water, the density 
of the dimethylaminopropylcarbamylpentyl (C3-CS) ligands on the affinity support 
was determined (see below). Finally, C3-C5 affinity matrices were obtained with 
various ligand densities (40-100 pmol/ml of settled wet gel). The structure of the 
affinity matrix (C3-C5 matrix) is shown in Fig. 1. 
Assays 
Ligand densities of affinity matrices (pmoles of amine per ml of settled wet gel 
volume) were calculated from the hydrochloric acid titration curve of the sodium 
hydroxide equilibrated matrix . Is FVIII activity (VIII:C) was determined in a chro- 
mogenic substrate assay (Coatest factor VIII, KabiVitrum, Stockholm, Sweden). 
FVIII and vWf protein concentrations [factor VIII antigen (VIII:Ag) and vWf anti- 
gen (vWfAg), respectively] were determined in sandwich enzyme-linked immunosor- 
bent assays (ELISAs) using monoclonal antibodies directed against factor VIII 
(CLB-CAg-A and CLB-CAg-117) and vWf (CLB-RAg-20 and CLB-RAg-35), re- 
spectively. Coagulation factors II, VII, IX and X were determined with assaysi6-l8 
,W 
Sepharose-O-t-y-(CH2)ii-y-(CH2)iN, 
OH OH CH3 
Fig. 1. Structure of the C3-C5 affinity ligand. 
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using artificial substrate plasmas for FII and FX, congenitally deficient substrate 
plasma for VFII and immunodepleted substrate plasma for FIX determination. The 
vWf multimeric structure was analysed using agarose gel electrophoresis”. 
The vWf activity [vWf-associated ristocetin cofactor activity (vWf:RCo)] was 
determined by ristocetin-induced agglutination of washed platelets”. A normal plas- 
ma pool, calibrated against 30 normal plasmas, was used as a standard in all assays 
for coagulation factors, vWfi RCo and vWf:Ag. Traces of thrombin, if present, were 
determined by adding a 0.3% (w/w) fibrinogen solution (KabiVitrum) to an equal 
volume of sample. One mixture was incubated for 20 h at 24°C and one for 6 h at 
37°C. After incubation, the mixtures were checked for fibrin formation. Albumin, 
IgG, IgA and IgM were determined in a nephelometer analyser (Behring, Marburg, 
F.R.G.). Fibrinogen, fibronectin and factor II antigen concentrations were deter- 
mined by single radial immunodiffusion*i, using specific antisera (CLB). Ci-esterase 
inhibitor activity was determined in a chromogenic substrate assay (Behrichrom, 
Behring, R.R.G.). Total protein content was determined with the BCA-protein assay 
(Pierce, Rockford, IL, U.S.A.), using purified human serum albumin (CLB) as a 
protein standard. 
Chromatographic procedures 
Batch-wise adsorption of plasma proteins onto the DEAE-Sephadex A-50 ion 
exchanger was achieved by adding various amounts of plasma to the pre-swollen 
matrix [26.7 g of dry ion exchanger per litre of 0.9% (w/v) sodium chloride]. The 
adsorption was carried out for 15-90 min at 15°C. After separation of the anion 
exchanger from the plasma using 20-pm netting (Type NY-20-hc, ZBF, Rueschlikon, 
Switzerland), the ion exchanger was suspended in buffer A (Table I) and poured into 
a chromatographic column. After settling of the gel, the anion exchanger was washed 
with buffer A at a flow-rate of 24 cm/h. Proteins, such as FII, FIX and FX, were 
desorbed from the DEAE-Sephadex by elution, at the same flow-rate, with four 
column volumes of buffer B (Table I). 
Batch-wise adsorption of plasma proteins onto the C3-C5 matrices was 
achieved by “end-over-end” mixing of at least 2 ml (wet gel volume) of equilibrated 
matrix (buffer E, Table I, x = 175 mA4) with various amounts of plasma. Adsorption 
times varied from 5 min to 6 h (adsorption temperature 20°C). The C3-C5 matrix, 
separated from the supernatant plasma by centrifugation (3 g, 5 min), was transferred 
to a column and after settling the gel was washed (3-6 bed volumes) and proteins 
(e.g., FVIII) were eluted (610 bed volumes) at a flow-rate of 30-60 cm/h. For the 
buffers applied, see Results. For column-wise adsorption, the C3-C5 matrix was 
packed under pressure (0.15 bar) and equilibrated with buffer E (Table I, x = 175 
mM). Fresh thawed plasma (volume 18-35 times the bed volume) was incubated 
batch-wise for 60 min at 15°C with preswollen DEAE-Sephadex A-50 (0.5 g of ion 
exchanger per kg of plasma). After filtration (0.5~pm filter, Profile type RlfO05; Pall, 
Portsmouth, U.K.), the filtrate was applied to the affinity matrix at a flow-rate of 30 
cm/h. After protein adsorption, the matrix was washed with 3-6 column volumes of 
buffer E (Table I, x = 175 mM) and proteins were desorbed by elution with 5-10 
column volumes of buffer D (Table I) at the same flow-rate. The desorption fraction 
of the C3-C5 matrix was concentrated and dialysed against buffer H (Table II) using 
a haemodialysis cartridge with a cut-off of 100 000 (type HF 40; Fresenius, Bad 
Homburg, F.R.G.). 
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TABLE II 
BATCH-WISE VERSUS COLUMN-WISE ADSORPTION OF FVIII ONTO THE C3-C5 MATRIX 
Pretreated plasma is adsorbed onto the C3-C5 matrix (ligand density 90 pmol/ml), column-wise washing 
with six bed volumes of buffer type C (see Table I), flow-rate 30-60 cm/h. Column-wise desorption with ten 
bed volumes of buffer type D, flow-rate 30 cm/h. 
Adsorption 
ripe 
Batch 
Column 
Time G: P ratio” 
(min) IW 
60 I:20 
60 I:25 
60 1:30 
360 1:20 
IO I:20 
220 I :20 
360 I:20 
450 1:25 
540 1:30 
630 1:35 
FVIII 
Adsorbed 
(%I 
>95 
85 
15 
195 
>95 
>95 
>95 
>95 
>95 
>95 
Desorhed 
CS, 
61 
55 
45 
51 
69 
61 
51 
49 
51 
35 
Prolein 
desorhcd 
(“/ui 
0.3 
0.3 
0.3 
0.4 
0.5 
0.5 
0.5 
0.5 
0.5 
0.4 
’ G:P ratio is the ratio (v/v) of C3-C5 matrix to plasma pretreated with 0.5 g of dry DEAE-Sephadex 
A-50 per kg of plasma. 
RESULTS 
Separation of coagulation factors II, IX and Xfrom factor VZZZ 
Under conditions such that FVIII is completely absorbed onto the C3-C5 ma- 
trix, other coagulation factors (II, IX and X) are simultaneously absorbed from 
plasma14. Therefore, in order to separate FII, FIX and FX from FVIII, an additional 
ion-exchange step with DEAE-Sephadex A-50 was introduced prior to adsorption of 
proteins onto the C3-C5 matrix. Fig. 2 shows the time-dependent kinetics of ad- 
0 
time (mm) 
Fig. 2. Time-dependent adsorption of coagulation factors II (O), VIII (0) and IX (a) from normal 
plasma onto DEAE-Sephadex A-50 at ratios of 0.75 (open symbols) and 0.50 (solid symbols) of dry 
DEAE-Sephadex A-50 per kg of plasma. Batch-wise adsorption at 15°C. 
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60 80 100 
llgand denstty ( pmol/ml) 
Fig. 3. Adsorption (0) and desorption (0) of VIII:C from the C3-C5 matrix and specific activity (s.a.) 
(0) of desorbed VIII:C as a function of the ligand density of the affinity matrix. Batch-wise incubation for 
1 h of 30 ml of plasma, pretreated with 0.5 g of dry DEAE-Sephadex A-50 per kg of plasma and 2 ml of 
C3-C5 matrix. Column-wise washing with 12 ml of buffer type C (see Table I) at a flow-rate of 60 cm/h. 
Column-wise desorption with 20 ml of buffer type D at a flow-rate of 30 cm/h at 20°C. 
sorption of coagulation factors II, VIII and IX onto the DEAE-Sephadex A-50 anion 
exchanger at two different ratios of anion exchanger to plasma (0.5 and 0.75 g of dry 
DEAE-Sephadex A-50 per kg of plasma). As the adsorption kinetics of FIX and FX 
are essentially the same, only the ad-/desorption data for FIX are presented. Fig. 2 
shows that an optimum separation of FVIII from FII and FIX can be obtained by 
using an incubation time of 60 min at a ratio of 0.5 g of anion exchanger per kg of 
plasma. Under these conditions, >90% of the coagulation factors II and IX are 
removed by adsorption onto the anion exchanger at the cost of a lo-15% loss of 
VIII:C in the unbound fraction. Plasma pretreated with DEAE-Sephadex A-50, as 
described above, is used as the starting material for the purification of FVIII by 
means of the C33C5 affinity matrix. 
Eflect of ligand density of the C3-C.5 matrix on purification of FVIII 
Results of batch-wise adsorption experiments with DEAE-Sephadex A-50 pre- 
treated plasma (Fig. 3) show that a minimum ligand density (>40 pmol/ml) is re- 
quired for adsorption of FVIII onto the C3-C5 matrix. For complete adsorption of 
FVIII (in 60 min at a gel-to-plasma ratio of 1:20, v/v), a ligand density of >80 
pmol/ml is necessary. The total protein ad-/desorption increases linearly with an 
increase in ligand density (results not shown). The optimum result with respect to 
recovery and s.a. of desorbed FVIII is obtained in the range 80-90 pmol/ml: 60% of 
FVIII is recovered, with an s.a. of 1.8 U VIII:C/mg protein (Fig. 3). 
EfSect of the composition of wash and desorption buglers on FVIII purity 
Varying the pH of the wash buffer between pH 6 and 8 shows that an optimum 
with respect to FVIII and protein recovered in the desorption fraction is reached 
between pH 7.0 and 7.5 (Fig. 4A). Increasing the sodium chloride concentration in 
the wash buffer from 100 to 250 mM results in a linear decrease in the amount of 
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A 
1, 
6 7 6 
PH 
100 200 
NaCl (mmol/l) 
Fig. 4. Effect of (A) pH and (B) NaCl concentration of wash buffer on desorption of VIII:C (0) and 
protein (a) from the C3-CS matrix. Batch-wise incubation for I h of 30 ml of plasma (pretreated with 0.5 g 
dry of DEAE-Sephadex A-50 per kg of plasma), 2 ml of C33C5 matrix (ligand density 90 pmol/ml); 
column-wise washing with 12 ml of buffer type F (A) or type E (B) ( see Table I) at a flow-rate of 60 cm. 
Column-wise desorption with 20 ml of buffer type D at a flow-rate of 30 cm/h at 20°C. 
protein desorbed; an optimum in terms of recovery of desorbed FVIII and effective 
removal of contaminating proteins by salt washing is obtained at a sodium chloride 
concentration between 150 and 175 mM (Fig. 4B). Fig. 5 shows that the optimum 
concentration of sodium chloride to be used in the desorption buffer, in terms of the 
maximum amount of desorbed VIII:C in combination with a minimum of total des- 
orbed protein, is in the range 0.75-1.25 M. 
‘ool----l o.5 
0 a0 4 1 1.5 
NaCl imol/l) 
Fig. 5. Effect of NaCl concentration in the elution buffer on desorption of VIILC (0) and protein (a) 
from the C33C5 matrix. Batch-wise incubation for I h of 30 ml of plasma (pretreated with 0.5 g of 
DEAE-Sephadex A-50 per kg of plasma), 2 ml of C3-C5 matrix (l&and density 90 pmol/ml); column-wise 
washing with I2 ml of buffer type E, X = 0.17 (see Table I), at a flow-rate of 60 cm/h. Column-wise 
desorption with 20 ml of buffer type G at a flow-rate of 30 cm/h at 20°C. 
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Batch-wise versus column-wise adsorption of FVIII 
The data in Table II indicate that a decrease in the matrix-to-plasma ratio at a 
constant batch-wise incubation time (1 h) results in a reduction in the amount of 
adsorbed and desorbed FVIII. The amount of desorbed total protein, however, is not 
affected by the matrix-to-plasma ratio. The ratio of 1:20 for the latter is the minimum 
applicable under these conditions. Prolongation of the incubation time from 60 to 360 
min results in a decrease in the amount of FVIII desorbed, whereas the amount of 
protein desorbed is slightly increased. The results of the column-wise adsorption of 
FVIII reveal that an extension of the contact time, by increasing the bed height of the 
column, or an increase in the amount of plasma applied to the matrix has an adverse 
effect on the amount of desorbed FVIII, whereas the amount of total protein de- 
sorbed is not affected. 
Scaling up of FVIII pur$cation process 
Batch-wise adsorption and column-wise desorption experiments were scaled up 
from an initial gel volume of 2 ml up to 200 ml. Column-wise adsorption and de- 
sorption experiments were scaled up from 10 ml to a gel volume of 1000 ml. In all 
experiments, plasma pretreated with DEAE-Sephadex A-50 was used as the FVIII 
source. The amount of plasma applied was usually 15-25 times the gel volume. Prior 
to column-wise adsorption, the starting material was filtered. Results of scale-up 
experiments (Table III) show that the FVIII recovery and the amount of total protein 
desorbed from the C3-C5 matrix are independent of scale size. 
Characterization of FVIII concentrate 
The FVIII concentrate, obtained from concentration and dialysis of the eluate 
of the C3-C5 matrix, contained 35 U VIII:C/ml with a specific activity of 1.2 U 
VIII:C/mg protein. Analysis of vWf:RCo, vWf:Ag and FVIII:Ag revealed (see Table 
IV) that the VIII:C/VIII:Ag, VIII:C/vWF:RCo and vWf:RCo/vWf:Ag ratios are 
TABLE III 
SCALING UP OF PROCESS PARAMETERS FOR FVlll PURIFICATION FROM PLASMA WITH 
THE C33C5 AFFINITY MATRIX 
Adsorption from plasma (pretreated with 0.5 g of dry DEAE-Sephadex A-50 per kg of plasma) onto 
C3-C5 matrix (ligand density 90 pmol/ml), batch-wise adsorption in 1 h, column-wise adsorption at a 
flow-rate of 30 cm/h. Column-wise washing with six bed volumes of buffer type C (see Table I), flow-rate 
30-60 cm/h. Column-wise desorption with ten bed volumes of buffer type D, flow-rate 30 cm/h. 
C3&CS matrix 
(ml1 
Plasma 
(ml) 
Factor VIII 
recovery (%)” 
Protein 
recovery (%)” 
Process time 
(hl 
2 30 51 0.30 2 
IO 200 58 (55) 0.30 (0.53) 2 (9) 
20 400 61 (51) 0.3 1 (0.49) 5 (9) 
100 2000 52 (57) 0.33 (0.40) 5 (8) 
200 4000 (56) (0.50) (11) 
1000 20 000 (52) (0.46) (11) 
’ Recovery compared with the amount in plasma. Data in parentheses are for column-wise ad- 
sorption and desorption. 
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TABLE IV 
CHARACTERIZATION OF FVIII CONCENTRATE ISOLATED BY AFFINITY PURIFICATION 
WITH C3-C5 MATRIX 
Protein Amount per ml Recovery (%)” 
VIII:C 35 u 46 
VIII:Ag 42 U 55 
vWf:RCo 40 u 50 
vWf:Ag 44 u 55 
Fibronectin 5.2 mg 
Fibrinogen 5.0 mg 
Prothrombin 0.6 mg 
IgG 1.2 mg 
IgA 0.3 mg 
IgM 3.2 mg 
Albumin 3.2 mg 
Total protein 29 mg 
’ Recovery relative to starting plasma. 
close to unity. Further, the vWf multimeric pattern of the concentrate (data not 
shown) is the same as that of the starting plasma. In addition to FVIII and vWf, 
fibronectin, fibrinogen, IgM, albumin and trace amounts of IgG, IgA and FII were 
present in the FVIII concentrate (Table IV). These contaminants constitute about 
70% of the total amount of protein present. Under the conditions used, neither FVII 
nor Ci-esterase inhibitor adsorbed onto the C33C5 matrix. 
DISCUSSION 
Separation of coagulation factors II, IX and Xfrom factor VIII 
Similarly to the use of FVIII concentrates in the treatment of haemophilia A, 
FIX concentrates are applied for treatment of haemophilia B patients. Commonly 
FIX concentrates are prepared by ion-exchange chromatography of the supernatant 
plasma after cryoprecipitation 22--24 Since FVIII and FIX, present in plasma, both . 
adsorb onto the C3-C5 matrix and are difficult to separate by means of step-wise 
sodium chloride elutioni4, an additional separation step is needed when both FVITI 
and FIX concentrates are to be produced. For this purpose, ion-exchange chromato- 
graphy with DEAE-Sephadex A-50 was implemented prior to application of the 
plasma onto the C3-C5 matrix. At DEAE-Sephadex-to-plasma ratios of 0.5-0.75 (g 
dry DEAE-Sephadex per kg plasma), both FII and FIX are removed from plasma 
relatively fast (Fig. 2). The similarity in the adsorption behaviour of these coagulation 
factors was also observed by Heystek et al. 23 Under these conditions, the adsorption .
of FVIII is much slower, and the loss of FVIII during the 60-min incubation is limited 
to lo-15%. Differences in adsorption rate of FII, FIX and FVIII, at low ratios of ion 
exchanger to plasma, are probably due to the large size difference between FIX and 
FII (Mr < 1 . lo5 kDa) on the one hand and FVIII, which is complexed to vWf (Mr 
> 1 . lo6 kDa), on the other. The size of the protein not only affects the diffusion rate 
but also excludes the larger proteins from penetration into the smaller pores of the ion 
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exchanger. At a ratio of 0.5 g of DEAE-Sephadex A-SO/kg pf plasma, an effective 
separation between FIX and FVIIT is obtained in 1 h. FIX is adsorbed to the extent of 
~90% whereas FVIII adsorption is less than 15%. Although FVIII adsorption in 
this step means a direct loss, the overall recovery after desorption from the C3-C5 
matrix (57%, Table III) is only slightly lower than that with normal plasma when 
directly contacted with the C3-C5 matrix and eluted therefrom (62%14). An addi- 
tional advantage of treatment of plasma with DEAE-Sephadex A-50, prior to ad- 
sorption onto the C33C5 matrix, is that the binding capacity for FVIII on the C3-C5 
matrix is increased from 10 U VIII:C/ml ge114 to 16 U VIII:C/ml gel (ligand density 
90 pmol/ml). Further, the s.a. of desorbed FVIII is improved from 1.2 U VIII:C/mg 
protein14 to 2.1 U VIII:C/mg protein. The s.a. of the FIX preparation eluted from 
DEAE-Sephadex A-50 (recovery 55%) is 2.5 U FIX/mg protein. Owing to the low 
ratio of DEAE-Sephadex A-50 to plasma, this s.a. of FIX is better than that for 
preparations obtained by reported procedures (1.0-1.5 U FIX/mg protein22P24). 
L$%ct of ligand density 
For the determination of the optimum ligand density of the C33C5 matrix, a 
compromise is made between s.a., adsorption time, economics and recovery. Com- 
pared with high ligand densities, the lower ligand densities give a higher s.a. at lower 
yields (Fig. 3) and need longer adsorption times and/or higher matrix-to-plasma 
ratios (data not shown). As a matrix-to-plasma ratio of 1:20 (v/v) is considered to be 
the maximum for production purposes, a ligand density of 90 pmol/ml is required to 
give fast and complete adsorption of FVIII. At this ligand density, the s.a. of de- 
sorbed FVIII still meets our goals. It is remarkable that, independent of the ligand 
density applied, the ratio of desorbed to adsorbed FVIII is a constant factor (0.65). 
This sets clear limits to the maximum recovery of FVIII in this type of chroma- 
tographic process step. Nevertheless, this result is better than that with chromatogra- 
phy of FVIII on aminohexyl-Sepharose, where a ratio of co.50 is found25,26. 
EfSect of composition of the wash and desorption hufSer 
Because the developed purification method for FVIII described is for process- 
scale chromatography, the compositions of the buffers are kept relatively simple. 
Variations in pH (6.0-8.0) and sodium chloride concentration (100-1500 mM) in the 
buffers are limited owing to the lability of FVIII. The optimum sodium chloride 
concentration in the wash buffer is 170 mM; higher sodium chloride concentrations 
result in desorption of FVIII and at lower concentrations removal of contaminating 
proteins is not as effective. The optimum pH of the wash buffer in combination with a 
sodium chloride concentration of 170 mMis 7.4. At higher pH the FVIII is less stable, 
resulting in denaturation of FVIII, and at lower pH more protein, including FVIII, is 
washed from the matrix. These results are in accordance with results obtained with 
aminohexyl-Sepharose . 2s*26 Variation of the sodium chloride concentration in the 
desorption buffer had a minor effect on the s.a. of FVIII. As the desorption of FVIII 
is tailing at low sodium chloride concentration, a sodium chloride concentration in 
the desorption buffer of 1 A4 is used as an optimum concentration with respect to 
FVIII recovery. 
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Butch-wise versus column-wise adsorption of FVIII and scaling up of process param- 
eters for FVIII put$cation 
The results in Table II show that batch-wise and column-wise adsorption (same 
adsorption time) differ mainly in the total amount of protein (adsorbed and) de- 
sorbed. There are also differences in the final FVIII recovery, but these seem to be 
caused by the longer process time and are independent of the adsorption principle. 
For the choice of the adsorption mode to be applied on a production scale, where 
plasma volumes of 750-1000 1 are processed, not only aspects such as recovery and 
purity are important parameters, but also whether the process meets GMP require- 
ments12. From the latter point of view, it may be clear that a batch-wise adsorption 
process, despite its higher recovery and purity, is not to be preferred. Therefore, 
column-wise adsorption is chosen as the adsorption mode for further scaling up. This 
choice has an impact on the process time. As the maximum flow-rate is not limited by 
the adsorption kinetics of FVIII, it is determined by the maximum flow-rate at which 
the C3-C5 matrix, i.e., Sepharose CL-4B, can be operated. A bed height of 10 cm, 
which can still be used on a process scale, and a sample volume of 20 column volumes 
results in an adsorption time of 667 h. Scaling up experiments with the C3-C5 matrix 
(Table III) show that despite the long process time for column-wise adsorption and 
desorption, the FVIII recovery is > 50% and the purity of the eluate is > 1 U VIII:C/ 
mg protein. These parameters are independent of the process scale, which offers good 
prospects for further scaling up. 
Characterization of FVIII concentrate 
The overall recovery after concentration and dialysis of the eluate of the C3-C5 
matrix is 46%, which is an improvement over the FVIII preparations obtained by 
cryoprecipitation, where recoveries of 40% are common3. The s.a. of the concentrate 
is > 1.0 U VIII:C/mg protein, which is higher than that obtained with cryoprecip- 
itation (0.3 U VIII:C/mg protein) and comparable to the s.a. of common intermedi- 
ate-pure FVIII concentrates, prepared from cryoprecipitate at a much lower ( > 20%) 
FVIII recovery3. The quality of the concentrated FVIII preparation is good as the 
VIII:C-to-VIII:Ag ratio is close to unity, indicating that the amount of inactive FVIII 
is low. The same holds true for the vWf:RCo-to-vWf:Ag ratio, indicating that all vWf 
present in the concentrate is active. The FVIII-to-vWf ratio is also 1.0, which is 
favourable for preservation of VIII:C as FVIII is stabilized by vWf. In comparison 
with common intermediate-pure FVIII concentrates, these data are better, as in most 
of these concentrates the VIII:C-to-VIII:Ag and vWf:Rco-to-vWf:Ag ratios are < 1 .O 
and the FVIII-to-vWf ratio is > 1.0 27 The presence of high-molecular-weight mul- .
timers of vWf in the FVIII concentrate implies that this preparation, in contrast to 
other FVIII concentrates, can also be of use in the treatment of von Willebrand’s 
disease. 
CONCLUSION 
With the purification method described, an FVIII concentrate can be obtained 
with a high yield and a relatively high yield and a relatively high s.a. as compared with 
cryoprecipitation. The process can meet GMP requirements, is reproducible and has 
the potential for automation. The implementation of the FVIII purification method 
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into the fractionation of plasma has no negative effects on the purification of FIX 
(prepared from the DEAE-Sephadex A-50 desorption fraction), FVII and Ci-ester- 
ase inhibitor, albumin and immunoglobulins which are present in the unbound frac- 
tion of the C33C5 affinity matrix. Therefore, this affinity chromatographic method 
for FVIII purification from plasma has great potential for replacing cryoprecipita- 
tion. Further optimization of the method will be carried out with respect to reduction 
of the process time of elimination of blood-borne viruses, such as human immunode- 
ficiency virus (HIV), hepatitis B virus and hepatitis non-A, non-B virus3. 
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